Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 12 04:00PM ET
3.56
Dollar change
-0.08
Percentage change
-2.20
%
IndexRUT P/E- EPS (ttm)-0.43 Insider Own22.22% Shs Outstand189.44M Perf Week-1.93%
Market Cap674.59M Forward P/E- EPS next Y-0.34 Insider Trans-0.02% Shs Float147.38M Perf Month-2.20%
Income-76.70M PEG- EPS next Q-0.08 Inst Own53.49% Short Float3.95% Perf Quarter-20.36%
Sales6.74M P/S100.09 EPS this Y11.82% Inst Trans5.45% Short Ratio5.77 Perf Half Y12.66%
Book/sh0.56 P/B6.31 EPS next Y11.86% ROA-51.29% Short Interest5.82M Perf Year73.66%
Cash/sh0.67 P/C5.28 EPS next 5Y- ROE-67.81% 52W Range1.98 - 4.72 Perf YTD42.40%
Dividend Est.- P/FCF- EPS past 5Y18.41% ROI-67.77% 52W High-24.66% Beta1.78
Dividend TTM- Quick Ratio7.02 Sales past 5Y55.33% Gross Margin79.15% 52W Low79.80% ATR (14)0.15
Dividend Ex-Date- Current Ratio7.02 EPS Y/Y TTM8.60% Oper. Margin-1165.03% RSI (14)45.46 Volatility3.77% 4.13%
Employees73 Debt/Eq0.06 Sales Y/Y TTM-69.69% Profit Margin-1137.64% Recom1.40 Target Price5.20
Option/ShortYes / Yes LT Debt/Eq0.06 EPS Q/Q13.08% Payout- Rel Volume0.66 Prev Close3.64
Sales Surprise-28.00% EPS Surprise-6.38% Sales Q/Q-71.25% EarningsNov 06 BMO Avg Volume1.01M Price3.56
SMA200.27% SMA50-5.49% SMA2003.82% Trades Volume661,391 Change-2.20%
Date Action Analyst Rating Change Price Target Change
Feb-02-22Upgrade Jefferies Hold → Buy $5
Feb-25-21Initiated Jefferies Hold $5
Dec-17-20Initiated H.C. Wainwright Buy $10
Jul-27-20Resumed JMP Securities Mkt Outperform $10 → $8
Jul-24-20Downgrade Robert W. Baird Outperform → Neutral
May-19-20Upgrade Wedbush Neutral → Outperform
Mar-06-20Upgrade Chardan Capital Markets Neutral → Buy $5
Feb-20-20Initiated Robert W. Baird Outperform $8
Feb-05-20Upgrade JMP Securities Mkt Perform → Mkt Outperform $10
Oct-07-19Reiterated B. Riley FBR Buy $7 → $3
Dec-06-24 08:20AM
Dec-03-24 08:00AM
Nov-26-24 07:30AM
Nov-15-24 11:02AM
11:01AM
07:30AM Loading…
Nov-14-24 07:30AM
Nov-07-24 02:12AM
02:07AM
Nov-06-24 08:45AM
07:40AM
07:30AM
Oct-23-24 07:30AM
Oct-15-24 08:16AM
Oct-01-24 07:30AM
Sep-25-24 09:40AM
07:30AM Loading…
Sep-03-24 07:30AM
Aug-22-24 09:40AM
Aug-06-24 09:40AM
Aug-02-24 01:51AM
Aug-01-24 08:40AM
07:41AM
07:30AM
Jul-18-24 07:30AM
Jun-06-24 11:15AM
11:15AM
Jun-05-24 02:30AM
May-29-24 07:30AM
May-22-24 02:00AM
May-17-24 12:03PM
10:40AM
09:00AM Loading…
09:00AM
May-07-24 07:30AM
May-03-24 11:19AM
03:24AM
May-02-24 12:55PM
08:58AM
08:45AM
07:44AM
07:30AM
07:25AM
Apr-30-24 09:40AM
Apr-18-24 07:30AM
Apr-04-24 08:30AM
Mar-08-24 07:30AM
Mar-01-24 08:17AM
Feb-29-24 11:14PM
08:40AM
07:52AM
07:30AM
Feb-15-24 07:30AM
Jan-08-24 07:30AM
Nov-09-23 04:24PM
04:01PM
09:12AM
Nov-08-23 07:30AM
01:16AM
Nov-07-23 08:05AM
07:40AM
07:30AM
07:15AM
Oct-30-23 09:32AM
Oct-24-23 07:30AM
Oct-18-23 07:30AM
Oct-11-23 08:05AM
Sep-12-23 10:56AM
08:58AM
Sep-11-23 04:15PM
Sep-07-23 07:30AM
Aug-04-23 03:29PM
Aug-03-23 08:55AM
07:49AM
07:30AM
Jul-23-23 10:19AM
Jul-20-23 07:30AM
Jul-12-23 07:30AM
Jul-10-23 04:01PM
Jun-23-23 09:40AM
Jun-21-23 07:30AM
02:01AM
Jun-07-23 09:40AM
02:01AM
Jun-01-23 11:29AM
May-31-23 07:30AM
May-30-23 09:26AM
May-29-23 10:08AM
May-22-23 09:40AM
May-17-23 07:38AM
May-09-23 12:00PM
07:30AM
May-04-23 11:52PM
09:40AM
08:55AM
07:30AM
Apr-27-23 03:20AM
Apr-25-23 11:57AM
11:50AM
07:30AM
Apr-20-23 07:30AM
Apr-18-23 04:01PM
02:18PM
Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the Hepatitis B virus, SARS-CoV-2, and other coronaviruses. The company was founded on October 6, 2005 and is headquartered in Warminster, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MANCHESTER KEITH SDirectorAug 14 '24Option Exercise0.5654,91530,75254,915Aug 16 04:07 PM
MANCHESTER KEITH SDirectorAug 14 '24Sale3.698,84632,63746,069Aug 16 04:07 PM
Sims KarenChief Medical OfficerFeb 02 '24Sale2.314,35810,078125,542Feb 05 07:55 PM
HASTINGS DAVID CChief Financial OfficerFeb 02 '24Sale2.319,59322,184181,907Feb 05 07:54 PM
Sofia Michael J.Chief Scientific OfficerFeb 02 '24Sale2.319,98223,0831,485,121Feb 05 07:54 PM
McElhaugh Michael J.Interim President & CEOFeb 02 '24Sale2.3110,16423,5041,504,793Feb 05 07:54 PM